RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Eyob, Henok ^a   Ekiz, Huseyin Atakan ^a   Welm, Alana L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antitumor immunity; CD8+ T cell response; Immunotherapy; Metastasis; MSP; RON; TNF; Tumor dormancy; Tumor microenvironment

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; MACROPHAGE STIMULATING PROTEIN; MATRIPTASE; RECEPTOR; RON PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNOSURVEILLANCE; LUNG METASTASIS; METASTASIS; MICROMETASTASIS; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84890263735     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25670     Document Type: Article

References (10)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013
2. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol- 031210-101324
3. Kretschmann KL, Eyob H, Buys SS, Welm AL. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets 2010; 11:1157-68; PMID:20545605; http:// dx.doi.org/10.2174/138945010792006825
4. Waltz SE, Eaton L, Toney-Earley K, Hess KA, Peace BE, Ihlendorf JR, et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest 2001; 108:567-76; PMID:11518730
5. Morrison AC, Wilson CB, Ray M, Correll PH. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol 2004; 172:1825- 32; PMID:14734766
6. Welm AL, Sneddon JB, Taylor C, Nuyten DSA, van de Vijver MJ, Hasegawa BH, et al. The macrophagestimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A 2007; 104:7570-5; PMID:17456594; http://dx.doi. org/10.1073/pnas.0702095104
7. Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Inhibition of Ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov 2013; PMID:23612011; http://dx.doi.org/10.1158/2159- 8290.CD-12-0480
8. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
9. Morrison AC, Correll PH. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J Immunol 2002; 168:853-60; PMID:11777982
10. Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 2010; 31:1181- 8; PMID:20694025; http://dx.doi.org/10.1038/ aps.2010.106